Results 91 to 100 of about 43,704 (225)

Frailty and Fitness in Older Adults With Acute Myeloid Leukemia: From Chronological Age to Multiparametric Assessment

European Journal of Haematology, EarlyView.
ABSTRACT Acute Myeloid Leukemia predominantly affects older adults, who often present with comorbidities, functional impairment, and frailty, limiting eligibility for intensive chemotherapy or allogeneic transplantation. Historically, treatment options were restricted to hypomethylating agents, low‐dose cytarabine, hydroxyurea, or supportive care, with
Antonella Bruzzese, Enrica Antonia Martino, Santino Caserta, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Ernesto Vigna, Massimo Gentile   +11 more
wiley   +1 more source

Advanced fibrosis, TP53 variants and acute/pure erythroid leukaemia: Diagnostic harbingers of ERCC6L2‐related bone marrow failure syndrome?

British Journal of Haematology, EarlyView.
Sai Sudha Valisekka, Meghan E. Lindstrom, Olivia J. Michel, Roy L. Kao   +3 more
wiley   +1 more source

Pronounced Reductions in Plasma Citrulline Indicate Severe Intestinal Mucosal Barrier Injury During Induction Therapy for Pediatric Acute Myeloid Leukemia

European Journal of Haematology, EarlyView.
ABSTRACT Objectives Pediatric acute myeloid leukemia (AML) chemotherapy regimens are frequently burdened by fever episodes, systemic inflammation and bloodstream infections (BSI). Mucosal barrier injury may contribute to these complications, but its role in childhood AML remains uninvestigated.
Carla Warley Kjær, Maria Ebbesen Sørum, Silvia De Pietri, Claus Moser, Malene Johanne Petersen, Marianne Hoffmann, Henrik Hasle, Sarah Weischendorff, Klaus Müller   +8 more
wiley   +1 more source

Optimization of Intra-Arterial Administration of Chemotherapeutic Agents for Glioblastoma in the F98-Fischer Glioma-Bearing Rat Model

Biomolecules
Glioblastoma (GBM) is a difficult disease to treat for different reasons, with the blood–brain barrier (BBB) preventing therapeutic drugs from reaching the tumor being one major hurdle.
Juliette Latulippe, Laurent-Olivier Roy, Fernand Gobeil, David Fortin   +3 more
doaj   +1 more source

KRAS Mutations Predict Inferior Post‐Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations

European Journal of Haematology, EarlyView.
ABSTRACT Somatic mutations in the MAPK signaling pathway are frequently identified at AML diagnosis; however, their impact on treatment resistance and long‐term survival remains unclear. We conducted a retrospective study of patients with newly diagnosed MAPK‐mutated AML seen at the University of Iowa Health Care.
Kensuke Takaoka, Sarah Mott, Ratdanai Yodsuwan, Sakditad Saowapa, Manasawee Tanariyakul, Chalothorn Wannaphut, Kittika Poonsombudlert   +6 more
wiley   +1 more source

Loss of DNA methylation is not associated with venetoclax–hypomethylating agents synergy in acute myeloid leukaemia cells

British Journal of Haematology, EarlyView.
Aida Selimović‐Pašić, Lisa Haglund, Maike Bensberg, Júlia Goldmann, Padraig D'arcy, Sandra Hellberg, Colm E. Nestor   +6 more
wiley   +1 more source

Mitochondrial transfer in acute myeloid leukaemia and multiple myeloma: Mechanisms, consequences and potential therapeutic opportunities

The FEBS Journal, EarlyView.
Mitochondria can be transferred from bone marrow cells to cancer cells in acute myeloid leukaemia and multiple myeloma, boosting tumour energy production, growth, and drug resistance. This review highlights key transfer mechanisms and shows how targeting mitochondrial movement and dynamics may offer new therapeutic strategies to limit cancer ...
Ebubechukwu Nwarunma, Mark T. S. Williams   +1 more
wiley   +1 more source

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties

International Journal of Nanomedicine, 2019
Lawrence D Mayer, Paul Tardi, Arthur C LouieJazz Pharmaceuticals, Inc., Palo Alto, CA, USAAbstract: Combination regimens are a standard of care for many cancers.
Mayer LD, Tardi P, Louie AC
doaj  

CD36‐mediated lipid rewiring in the metabolic adaptation of tumour ecosystems

The FEBS Journal, EarlyView.
Nutrient deprivation drives a lipid‐centric shift in tumour metabolic symbiosis and signalling network. CD36 functions as a bidirectional bridge, transferring fatty acids from stromal donors (adipocytes, CAFs) to the ecosystem tumour‐ and microenvironment‐dependently.
Anna Sebestyén, Viktória Varga, Fatime Szalai, Risa Miyaura, Nóra Förhécz, Bálint Csikós, Rebeka Gelencsér, Zsófia Gábriel, Timea Komlódi, Katalin Dezső, Ildikó Krencz, Dorottya Moldvai   +11 more
wiley   +1 more source

Benign by design: A paradigm shift in cosmetic ingredient development

International Journal of Cosmetic Science, EarlyView.
Benign by design strategies enable the creation of biodegradable cosmetic ingredients, reducing environmental persistence while maintaining the intended biological activity. This work compiles design rules and tools to guide the development of more sustainable molecules for the cosmetics industry.
Sandra Mota, Klaus Kümmerer, Isabel Martins de Almeida, Emília Sousa   +3 more
wiley   +1 more source